Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Clenbuterol

The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).

Trial Locations (1)

27705

Duke University Medical center, Durham

All Listed Sponsors
lead

Dwight Koeberl, M.D., Ph.D.

OTHER

NCT04245709 - Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter